ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis

Kim, Mi Na; Lee, Jae Seung; Lee, Hye Won; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Jang, Se Young; Tak, Won Young; Kweon, Young-Oh; Park, Soo Young; Kim, Seung Up

doi:10.1016/j.cgh.2022.10.035

Record: found
Abstract: not found
Article: not found

ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis

Author(s): Mi Na Kim , Jae Seung Lee , Hye Won Lee , Beom Kyung Kim , Jun Yong Park , Do Young Kim , Sang Hoon Ahn , Se Young Jang , Won Young Tak , Young-Oh Kweon , Soo Young Park , Seung Up Kim

Publication date Created: November 2022

Publication date (Print): November 2022

Journal: Clinical Gastroenterology and Hepatology

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We investigated whether baseline and on-treatment alanine aminotransferase (ALT) levels during entecavir (ETV) therapy are associated with achieving subcirrhotic liver stiffness (LS) and hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV)-related cirrhosis.